Selective NaV1.6 Blockade in Epilepsy Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiepileptic drugs targeting voltage-gated sodium channels are non-selective, leading to unintended effects and reduced efficacy, as they block all NaV channel isoforms indiscriminately, including NaV1.1, which can be proconvulsant, and NaV1.6, which may be anticonvulsant, necessitating the development of more selective treatments for epilepsy and related conditions.
Innovation Solution
A pharmaceutical formulation comprising (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide (Compound A) or its pharmaceutically acceptable salt, administered in various dosage forms such as immediate release tablets, granular formulations, and multiparticulate sprinkle dosage forms, specifically targeting NaV1.6 activity to treat epilepsy and associated pathological states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective NaV channel antagonists are used, then broad coverage of sodium channel isoforms is achieved, but selective blockade of NaV1.6 is lost leading to unintended effects
Solution Approach 1:
The patent applies local quality by designing a compound with specific molecular features (S-configur ation at the benzy lpyrrolidinyl ring, fluorine substitution at the 2-position of the benzenesulfonamide ring, and thiazol-4-yl substitution at the N-position) that confer selective affinity for NaV1.6 channels over other isoforms. This localized structural modification enables the drug to differentiate between channel isoforms and selectively target NaV1.6, resolving the contradiction between broad coverage and selective blockade.
2Power
If all NaV channel isoforms are blocked indiscriminately, then comprehensive sodium channel antagonism is achieved, but proconvulsant effects from NaV1.1 blockade occur
Solution Approach 1:
The patent extracts the harmful effect by selectively isolating the therapeutic target (NaV1.6) from the broader class of sodium channel isoforms. The compound's molecular structure is specifically optimized to interact with unique features of the NaV1.6 channel, thereby extracting the desired anticonvulsant effect while leaving other isoforms like NaV1.1 unaffected, thus eliminating the proconvulsant side effect.
3Reliability
If non-selective NaV blocking drugs are administered, then general anticonvulsant activity is achieved, but therapeutic index is reduced due to off-target blockade
Solution Approach 1:
The patent applies parameter changes by modifying key molecular parameters of the compound: the S-configuration at the benzy lpyrrolidinyl ring, the fluorine atom position (2-position), and the thiazol-4-yl group substitution. These parameter modifications shift the compound's binding profile to preferentially interact with NaV1.6 channels, thereby maintaining anticonvulsant activity while minimizing off-target effects and improving the therapeutic index.
Data Source
AI summary
Provided herein are certain pharmaceutical compositions comprising (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzene-sulfonamide (Compound A), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. The pharmaceutical compositions can be present in form of an immediate release tablet, a granular formulation, a stable suspension oral dosage form or a multi-particulate sprinkle dosage form. Methods for the treatment of a disease or a condition associated with Naj4.6 activity, such as epilepsy, are described.